Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

the Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03548129
Recruitment Status : Active, not recruiting
First Posted : June 7, 2018
Last Update Posted : June 7, 2018
Sponsor:
Information provided by (Responsible Party):
mohammed mahmoud samy, Ain Shams University

Brief Summary:
Urinary tract infections (UTIs) are the most commonly occurring bacterial infections in women, Asymptomatic bacteriuria (AB) is a common complication during pregnancy, with a prevalence of 2-10%. It has been associated with a greater incidence of symptomatic urinary tract infection (UTI), as well as foetal and obstetric complications. Appropriate treatment reduces the incidence of UTI by 80-90%, as well as the risk of a premature birth and low-birth-weight baby Fosfomycin trometamol (Monuril) is approved in numerous countries worldwide, including various European countries and the USA, mainly for the treatment of uncomplicated UTIs

Condition or disease Intervention/treatment Phase
Urinary Tract Infection Drug: phosphomycin Drug: Culture specific antibiotic therapy Diagnostic Test: Pre-treatment Urine Culture Diagnostic Test: Antimicrobial sensitivity testing Diagnostic Test: Post-treatment urine culture Phase 2

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: Empirical Use of Fosfomycin as a Single Dose Oral Treatment of Asymptomatic Bacteriuria
Study Start Date : July 2016
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : August 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Fosfomycin group (FG)

Pre-treatment Urine culture will be done then all patients will receive empirical 3 gm oral phosphomycin fosfomycin will be taken by mouth on an empty stomach i.e. 2-3 hours after meals preferably in the evening before bed time after emptying the bladder.

The contents of 1 packet of Monuril will be dissolved in a glass of water or another non-alcoholic drink and drink immediately. Do not mix with hot water. Do not take fosfomycin in its dry form.

Response to treatment will be assessed by post-treatment urine culture.

Drug: phosphomycin
Single dose 3 gm oral fosfomycin will be taken by mouth on an empty stomach

Diagnostic Test: Pre-treatment Urine Culture
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.

Diagnostic Test: Post-treatment urine culture
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.

Active Comparator: Culture specific group (CG):

Pre-treatment Urine culture and antimicrobial sensitivity testing will be done then all patients will receive oral culture specific antibiotic therapy in the form of five days regimen.

Response to treatment will be assessed by post-treatment urine culture.

Drug: Culture specific antibiotic therapy
Culture-specific antibiotic treatment for 5 days

Diagnostic Test: Pre-treatment Urine Culture
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.

Diagnostic Test: Antimicrobial sensitivity testing
Susceptibility of urinary pathogens to various antimicrobials

Diagnostic Test: Post-treatment urine culture
Mid-stream urine sample will be cultured and number of CFU per mL will be determined.




Primary Outcome Measures :
  1. Resolution of asymptomatic bacteriuria [ Time Frame: 1 week ]
    Decline in colony forming unit (CFU)/mL or absence of bacterial growth after treatment


Secondary Outcome Measures :
  1. Need for further treatment [ Time Frame: 1 week ]
    Either extending the course of treatment into 5 or 7 days regimen or changing the antibiotic in case of inadequate initial response.

  2. Need for further investigations [ Time Frame: 1 week ]
    Need for urine culture and sensitivity in fosfomycin group in case of inadequate response on empirical treatment.

  3. Incidence of adverse drug reactions . [ Time Frame: 1 week ]
    Incidence of adverse drug reactions as nausea, diarrhea, headache, vaginal itching, runny nose, back pain Side effects from other antibiotics in culture and sensitivity group



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Pregnant patients from 13 weeks to 36 weeks gestation.
  2. Pus cells in urine analysis >5/HPF.
  3. ≥ 105 colony-forming units (CFU) per millilitre of the same microorganisms in two consecutive cultures.
  4. No symptoms or sings suggestive of urinary tract infection.

Exclusion Criteria:

  1. Presence of any urinary symptoms as burning micturition, hesitancy
  2. Fever and loin pain.
  3. Diabetes mellitus.
  4. Known to be allergic from any of the antimicrobial ingredients.
  5. Not using any antimicrobial during the course of treatment for any other infection.
  6. Not known to have any congenital urinary anomalies.
  7. If the patient is taking medications that interact with fosfomycin as:

    • Anorexiants (eg, phentermine) or certain sympathomimetics (eg, albuterol, amphetamine, pseudoephedrine) because the risk of their side effects may be increased by fosfomycin.
    • Lithium or tetracyclines because their effectiveness may be decreased by fosfomycin.
    • Metoclopramide because it may decrease fosfomycin's effectiveness.
  8. Impaired kidney functions (creatinine's clearance is <80 ml/min.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03548129


Sponsors and Collaborators
Ain Shams University
Investigators
Layout table for investigator information
Principal Investigator: Mohamed Samy, MD M Samy

Layout table for additonal information
Responsible Party: mohammed mahmoud samy, Lecturer in Obstetrics and Gynecology, Ain Shams University
ClinicalTrials.gov Identifier: NCT03548129     History of Changes
Other Study ID Numbers: phosphomycin
First Posted: June 7, 2018    Key Record Dates
Last Update Posted: June 7, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Tract Infections
Bacteriuria
Infection
Urologic Diseases
Anti-Bacterial Agents
Fosfomycin
Antibiotics, Antitubercular
Anti-Infective Agents
Antitubercular Agents